Stock Yearly Return 2020
Start date: 12/31/2019
End date: 12/31/2020
Start price/share: $30.62
End price/share: $57.20
Dividends collected/share: $0.00
Total return: 86.81%
Average Annual Total Return: 86.49%
Starting investment: $10,000.00
Ending investment: $18,680.87
Years: 1.00


APLS average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
Compare APLS average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
Growth of $10,000.00
Without Dividends Reinvested Into APLS


Also see:
APLS YTD return
APLS average annual return 10 years
Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of therapeutic compounds to treat disease through the inhibition of the complement system at the level of C3. Co.'s primary product candidate, pegcetacoplan, is a conjugate of a compstatin analogue, formulated both for intravitreal administration by injections directly into the eye, and systemic administration by subcutaneous injection, which is an injection into the tissue under the skin. Co. is also developing APL-9 for the prevention of complement immune system activation coincident with adeno-associated virus vector administration for gene therapies and other indications. The APLS stock yearly return is shown above.

The yearly return on the APLS stock yearly return page and across the coverage universe of our site, is a measure of the annual return over the calendar year 2020 for the given stock. When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is more than just the change in price if that instrument pays a dividend or coupon.

One way to factor dividends into the return is simply to count them as cash — we don't do that here. Instead, our website aims to empower investors by performing the APLS annual return calculation with any dividends reinvested as applicable (on ex-dates).
Quotes delayed 20 minutes
Get Free SEC filing alerts for APLS:
APLS SEC Filing Email Alerts ServiceExternal link
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Apellis Pharmaceuticals (APLS) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

APRI Average Annual Return
APVO Average Annual Return
AQB Average Annual Return
AQXP Average Annual Return
ARA Average Annual Return
ARAY Average Annual Return
ARDM Average Annual Return
ARDX Average Annual Return
ARNA Average Annual Return
ARQL Average Annual Return
More Healthcare companies »

 

APLS Stock Yearly Return 2020 | www.AverageAnnualReturn.com | Copyright © 2021 - 2021, All Rights Reserved

Nothing in AverageAnnualReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.